Hold
Strong Buy
Buy
Hold
Sell
Strong Sell
0
3
8
1
0
Elevation Oncology, Inc. - Common stock
Share · US28623U1016 · ELEV (XNAS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Elevation Oncology, Inc. - Common stock
Analyst Grade Summary
No Price
Share Float & Liquidity
Free Float 73,44 %
Shares Float 43,51 M
Shares Outstanding 59,25 M
Company Profile for Elevation Oncology, Inc. - Common stock Share
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Company Data
Name Elevation Oncology, Inc. - Common stock
Company Elevation Oncology, Inc.
Symbol ELEV
Website
https://elevationoncology.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN US28623U1016
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Joseph J. Ferra Jr.
Market Capitalization 22 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 888 Seventh Avenue, 10106 Boston
IPO Date 2021-06-25
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | ELEV |
More Shares
Investors who hold Elevation Oncology, Inc. - Common stock also have the following shares in their portfolio:
